Thermo Fisher Scientific Inc. (TMO) Sees Large Increase in Short Interest

Thermo Fisher Scientific Inc. (NYSE:TMO) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,405,049 shares, an increase of 47.8% from the November 30th total of 3,657,291 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily volume of 2,174,965 shares, the days-to-cover ratio is presently 2.5 days.

A number of analysts recently issued reports on TMO shares. Cowen reiterated an “outperform” rating and set a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, October 26th. Leerink Swann boosted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Finally, Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $205.21.

Thermo Fisher Scientific (NYSE:TMO) opened at $196.52 on Thursday. Thermo Fisher Scientific has a 52-week low of $140.00 and a 52-week high of $201.20. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. The company has a market capitalization of $78,390.00, a PE ratio of 33.37, a P/E/G ratio of 1.55 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same period in the previous year, the business earned $2.03 earnings per share. The firm’s revenue was up 13.9% on a year-over-year basis. equities research analysts predict that Thermo Fisher Scientific will post 9.36 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.49% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Chevy Chase Trust Holdings Inc. boosted its holdings in shares of Thermo Fisher Scientific by 0.4% in the 2nd quarter. Chevy Chase Trust Holdings Inc. now owns 339,414 shares of the medical research company’s stock worth $59,218,000 after purchasing an additional 1,300 shares in the last quarter. Franklin Street Advisors Inc. NC boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 20,309 shares of the medical research company’s stock worth $3,543,000 after purchasing an additional 315 shares in the last quarter. Trust Co. of Oklahoma boosted its holdings in shares of Thermo Fisher Scientific by 1.8% in the 2nd quarter. Trust Co. of Oklahoma now owns 13,303 shares of the medical research company’s stock worth $2,321,000 after purchasing an additional 230 shares in the last quarter. Buffington Mohr McNeal boosted its holdings in shares of Thermo Fisher Scientific by 165.8% in the 2nd quarter. Buffington Mohr McNeal now owns 28,944 shares of the medical research company’s stock worth $5,050,000 after purchasing an additional 18,053 shares in the last quarter. Finally, Liberty Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 1.1% in the 2nd quarter. Liberty Capital Management Inc. now owns 19,168 shares of the medical research company’s stock worth $3,424,000 after purchasing an additional 202 shares in the last quarter. Institutional investors and hedge funds own 86.22% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/04/thermo-fisher-scientific-inc-tmo-sees-large-increase-in-short-interest.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply